10-16-2011, 04:54 PM
|
#3
|
Senior Member
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
|
Re: AZURE results --"do not support the routine use of zoledronic acid adjuv mngmt o
Commentary on the same study:
http://www.cancernetwork.com/breast-.../10165/1959178
Quote:
In a prespecified analysis, our finding of a possible benefit of [ZA] in patients who had undergone menopause more than 5 years before study entry is intriguing…and showed a small but significant survival advantage for patients who received [ZA]. Furthermore, the use of [ZA] appeared to have divergent effects on metastasis to visceral and locoregional sites according to menopausal status.” Analyses of the findings “suggest a systemic effect of [ZA] that operates differently according to menopausal status and that is distinct from any effect in bone,” they said, hypothesizing that “perhaps bone provides a sanctuary for cancer cells, and after treatment with [ZA], the ability of cancer cells to disseminate to other body sites is dependent on the presence of reproductive hormones.
|
|
|
|